Cystic fibrosis is a rare disease that affects about 30,000 people in the United is indicated for patients aged 2 and older who have one mutation in the CFTR gene that is responsive to drug treatment based on clinical and/or in vitro (laboratory) data. The expanded indication will affect another 3 percent of the cystic fibrosis population, impacting approximately 900 patients. Kalydeco serves as an example of how successful patient-focused drug development can provide greater understanding about a disease. For example, the Cystic Fibrosis Foundation maintains a 28,000-patient registry, including genetic data, which it makes available for research.
I have found SD to be a far superior alternative to Anadrol, as it is not only at least equally effective for increasing muscle fullness (more so in many instances), but it does not carry with it the same risk of sub-q water retention. Pure, properly compounded SD (20-30 mg/day) results in a hard, dense, and dry appearance, which works synergistically with the other orals mentioned above to ensure you come in as full and conditioned as possible. However, as with all steroids, I suggest experimenting with it prior to the competition in order to gauge its effects on your own body, as a small percentage of individuals do not respond as well to this drug. Another option is Dimethazine. This oral is closely related to SD (it is 2 SD molecules attached by an azine bond) and provides visually identical effects at a slightly higher dosage (45 mg/day).
This subject would not be complete if we did not touch on the ability of AAS to incite fat loss. There is much speculation in this arena, as many of the drugs BB’rs utilize during prep were never clinically studied in human beings, leaving us with the sometimes job of discerning which drugs work best. While anecdotal evidence has served us well over the years, the presence of a clinical study offers further confirmation that we have been on the right rack (or not). Fortunately, two of our most commonly used pre-contest drugs have been proven capable of increasing the rate of fat loss. These are testosterone and trenbolone. Trenbolone in particular has consistently demonstrated impressive results, which is why I almost always recommend its inclusion as a core injectable. Some individuals choose shy away from tren due to its high side effect profile, but for those who can tolerate the drug, few, if any drugs will offer an equal number of benefits during contest prep.
There has also been talk of terminating the use of all injectables at 2 weeks out. Advocates of this method claim that it is necessary for achieving optimal condition. The logic used to sustain this assertion is that injectables, by way of intramuscular delivery, result in a minor degree of water retention via increased inflammation. It is true that even slightly invasive procedures, such as an injection, will produce an inflammatory effect, but the level of inflammation necessary to result in a visible response is unlikely to occur when using non-irritating, sterile steroid preparations, especially when delivered with a 25 g. syringe or smaller. If anyone is worried about this, one can simply discontinue all injections at 3-4 days out. By the time the comp rolls around, the inflammation will no longer be present.